Company to integrate European diversity data from the UK and demographics data from France and Spain.
Anju, a clinical technical solutions provider, announced the expansion of its TA Scan platform through the integration of European diversity data from the UK and demographics data from France and Spain. According to a company press release, TA Scan enables users to visualize essential data, such as ethnicity, socio-economic information, and site/investigator experience, all on a single map.
"TA Scan's expansion into European diversity data underscores our commitment to helping clinical research professionals meet their global study diversification goals," said Barbara Argibay, VP, development, data division, Anju. "Empowering users to optimize recruitment strategies, site/investigator/KOL selection, and diversity initiatives with ease, while maintaining the highest standards of data security and privacy."
Reference: Anju's TA Scan Expands Global Reach with European Diversity Data Integration. PR Newswire. October 17, 2023, Accessed October 20, 2023. https://www.prnewswire.com/news-releases/anjus-ta-scan-expands-global-reach-with-european-diversity-data-integration-301959425.html
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.